Zicam Nasal Swab Recall | Check Your Lot Numbers Now

Manufacturing Standards at Zicam

Church & Dwight Co., Inc. has initiated a nationwide recall of 318,600 cartons of its popular over-the-counter cold remedy. The move follows an FDA inspection that identified significant departures from established Current Good Manufacturing Practice (CGMP) standards. Specifically, investigators discovered that the product failed to meet safety thresholds during routine microbiology testing. These swabs, marketed as a zinc-free homeopathic treatment, are sold as single-use applicators infused with cooling menthol and eucalyptus to provide relief from typical cold and flu symptoms.

While the recall process is mandatory for consumer protection, it highlights the technical requirements inherent in producing over-the-counter medical devices. The company is currently managing the logistics of removing these units from store shelves across the country. The FDA has officially classified this action as a Class II recall. This category applies when use or exposure to a product might cause temporary or medically reversible adverse health consequences for the user. Although no specific incidents of harm were detailed in the initial alert, the regulatory action acts as a safeguard against potential contamination.

Specific Products Affected by the Recall

The affected inventory consists of specific batches identified by the manufacturer. Consumers who purchased Zicam Cold Remedy Medicated Nasal Swabs are urged to check their cartons against the following lot numbers. The recalled products carry lot number UN52882 with an expiration date of April 30, 2028. Other affected units include lot number UN53431, which expires June 30, 2028, and lot number UN60411, set to expire August 31, 2028. Each carton contains 20 single-use swabs and is identified by UPC 732216301205.

Church & Dwight Co., based in Ewing, New Jersey, maintains responsibility for the distribution of these specific remedies. The sheer volume of the recall, nearing 320,000 cartons, suggests a broad distribution network that reaches pharmacies and grocery stores in most states. Retailers are expected to pull the remaining inventory from their shelves immediately to prevent further consumer access. For those holding these specific lots at home, industry experts recommend discontinuing use and returning the product to the place of purchase for a potential refund or disposal.

Regulatory Environment and Industry Context

Manufacturing protocols for over-the-counter health products are rigorous. When a company falls short of CGMP requirements, the FDA issues a recall notice to ensure that any potential risks to the public are neutralized quickly. Microbiological safety testing is a primary focus for regulatory bodies because nasal products require a level of sterility to prevent infection or irritation of sensitive mucous membranes. A departure from these standards often triggers an immediate review of the manufacturing site and the production lines responsible for the non-compliant batches.

This recall is one of many instances where national retailers and manufacturers must reconcile large-scale production with stringent federal safety guidelines. The incident serves as a reminder for consumers to remain vigilant regarding product alerts. While many people view over-the-counter remedies as low-risk, they remain subject to the same oversight as any other regulated health item. Moving forward, the focus will likely remain on whether Church & Dwight Co. can address the microbiological failures identified at the facility level and how quickly the supply chain can restore trust in the product line. As of now, the company has not provided a detailed statement regarding the specific nature of the microbial concerns, leaving the public to rely on the guidance provided by the FDA oversight team. Consumers should continue monitoring the FDA's official portal for any updates regarding the disposal process or further information on the specific hazards associated with these batches.